T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1826
Chemours
CC
$2.38B
| $1.68M | ﹤0.01% |
142,278
-1,747
| -1% | -$22.4K |
|
1827
Flywire
FLYW
$2.26B
| $1.67M | ﹤0.01% |
118,121
+12,764
| +12% | +$175K |
|
1828
Kinetik
KNTK
$4.31B
| $1.67M | ﹤0.01% |
46,392
+9,906
| +27% | +$358K |
|
1829
Liberty Global Class A
LBTYA
$3.61B
| $1.67M | ﹤0.01% |
149,993
+13,822
| +10% | +$153K |
|
1830
Collegium Pharmaceutical
COLL
$912M
| $1.67M | ﹤0.01% |
36,026
+1,061
| +3% | +$44.4K |
|
1831
Federated Hermes
FHI
$4.74B
| $1.67M | ﹤0.01% |
32,010
| – | – |
|
1832
Insperity
NSP
$1.99B
| $1.66M | ﹤0.01% |
42,942
+6,339
| +17% | +$253K |
|
1833
Vanguard Morningstar Growth ETF
VUG
$230B
| $1.66M | ﹤0.01% |
20,412
+366
| +2% | +$29.7K |
|
1834
Myers Industries
MYE
$1.23B
| $1.66M | ﹤0.01% |
88,363
+2,166
| +3% | +$38.5K |
|
1835
GlobalFoundries
GFS
$29.7B
| $1.65M | ﹤0.01% |
47,086
+3,725
| +9% | +$133K |
|
1836
iShares Core S&P Mid-Cap ETF
IJH
$128B
| $1.65M | ﹤0.01% |
24,916
| – | – |
|
1837
Omeros
OMER
$1.24B
| $1.64M | ﹤0.01% |
95,745
+6,217
| +7% | +$53.5K |
|
1838
NovaGold Resources
NG
$3.52B
| $1.64M | ﹤0.01% |
176,025
-3,442,840
| -95% | -$31.9M |
|
1839
Benchmark Electronics
BHE
$2.92B
| $1.64M | ﹤0.01% |
38,340
+1,792
| +5% | +$77.6K |
|
1840
Fastly Inc
FSLY
$4.75B
| $1.64M | ﹤0.01% |
161,020
+4,918
| +3% | +$48.5K |
|
1841
Northern Oil and Gas
NOG
$2.61B
| $1.64M | ﹤0.01% |
76,359
-4,842
| -6% | -$109K |
|
1842
TripAdvisor
TRIP
$1.28B
| $1.63M | ﹤0.01% |
112,115
+8,628
| +8% | +$131K |
|
1843
Digi International
DGII
$3.2B
| $1.63M | ﹤0.01% |
37,698
+1,826
| +5% | +$73.1K |
|
1844
FIVE9
FIVN
$2.45B
| $1.63M | ﹤0.01% |
81,366
+7,207
| +10% | +$153K |
|
1845
Marriott Vacations Worldwide
VAC
$4.22B
| $1.63M | ﹤0.01% |
28,213
-801
| -3% | -$47.3K |
|
1846
CTS Corp
CTS
$1.8B
| $1.61M | ﹤0.01% |
37,600
+802
| +2% | +$33.6K |
|
1847
iShares S&P Small-Cap 600 Value ETF
IJS
$8.45B
| $1.61M | ﹤0.01% |
14,156
| – | – |
|
1848
Hilltop Holdings
HTH
$2.28B
| $1.6M | ﹤0.01% |
47,185
+4,528
| +11% | +$152K |
|
1849
Rogers Corp
ROG
$2.52B
| $1.59M | ﹤0.01% |
17,395
+235
| +1% | +$20.2K |
|
1850
Tennant Co
TNC
$1.18B
| $1.59M | ﹤0.01% |
21,618
+1,696
| +9% | +$130K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.